The agreement will allow MediPharm to work with various clinician groups at McMaster, using its cannabis drug license to provide access to clinical trial material that meets pharmaceutical quality standards.

MediPharm Labs and McMaster University researchers have proposed three distinct clinical trials.

The initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD drug candidates for multiple indications including pain, insomnia associated with major depression, and uremic pruritus.

Keith Strachan, president and interim CEO of MediPharm Labs, commented on the partnership.

“As a pharmaceutical company specialized in cannabis, MediPharm Labs is excited to participate in the development of drugs containing cannabis,” he said.

“This will further our initiative to fulfill the global need for pharmaceutically approved drugs containing cannabis.”

MediPharm’s expertise in formulation and delivery methods will be critical in executing these trials.

Before each study begins, all necessary approvals from regulatory authorities, including Health Canada, will be obtained.

MediPharm Labs is a global leader in specialized, research-driven pharmaceutical-quality development and manufacturing of cannabis active pharmaceutical ingredient (API) products.

The company has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies, and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers.

MediPharm Labs Corp. (LABS) is down 1.04 per cent, trading at $0.475 per share as of 9:30 am ET.